08:45 AM EDT, 07/17/2024 (MT Newswires) -- Immutep ( IMMP ) said Wednesday it has received regulatory clearance from the Netherlands' ethics authority to begin human testing of its IMP761 potential autoimmune disease treatment.

Immutep ( IMMP ) describes IMP761 as a LAG-3 agonist antibody to potentially treat rheumatoid arthritis, type 1 diabetes, and multiple sclerosis, among other autoimmune diseases.

The company said the phase I study is being conducted by the Center for Human Drug Research in Leiden, the Netherlands, with the aim of enrolling 49 healthy volunteers to assess the safety and pharmacokinetics of IMP761.